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From the Editor’s Desk
PATIENTS AND TEACHING 
AND TRAINING
Recently, the relative peace of a public 
hospital clinic was shattered by the loud 
protestations of a patient. On being 
approached by a registrar and a medical 
student, he dismissed both out of hand. 
He was not going to be seen by “junior 
doctors!” He wanted a “real doctor — the 
specialist!”. Not surprisingly, this 
dismissal caused the registrar and 
student some distress.
Versions of this attitude are part and 
parcel of our teaching hospitals. Most 
medical students will remember 
instances of being dismissed by patients 
or sent away by guardians of the wards.
And with the ascendancy of 
consumerism and individual autonomy, 
patients choosing to not be part of 
clinical teaching or training may well 
become more common. This scenario is 
even more likely in light of increasing 
student numbers in a setting in which 
teaching resources are already stretched.
Should society expect its citizens to be 
involved in the teaching and training of 
future doctors? Some people argue that 
there is a moral obligation to participate 
in these activities. After all, society 
expects doctors to be competent and 
capable, and these attributes do not 
simply materialise.
Just as today’s patients reap the benefits 
of yesterday’s patients’ participation in 
clinical education, is it not reasonable 
that today’s patients reciprocate for the 
benefit of tomorrow’s patients? 
Unfortunately, the prevailing cult of the 
individual, which values “my choice” and 
“my rights”, places a correspondingly low 
value on the needs of the community.
Increasingly, medical schools are 
adding another leg to the three-legged 
stool they talk about — to teaching, 
research and patient care is added social 
accountability. 
But social accountability is a two-way 
street — particularly so in clinical 
teaching and training.
Martin B Van Der Weyden
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Letters
Sustained increase in infectious 
syphilis notifications in Victoria
Rebecca J Guy,* David E Leslie,† 
Kleete Simpson,‡ Beth Hatch§ 
Jennie Leydon,¶ Margaret E Hellard,** 
Heath A Kelly††
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and Population Health Research, Macfarlane Burnet 
Institute for Medical Research and Public Health, 
GPO Box 2284, Melbourne, VIC 3001; † Microbiologist, 
¶ Senior Serologist, †† Head, Victorian Infectious
Diseases Reference Laboratory, Melbourne, VIC; 
‡ Surveillance Manager, § Partner Notification Officer, 
Blood Borne Viruses and Sexually Transmissible 
Infections Program, Department of Human Services, 
Melbourne, VIC.
Rebecca.Guy@burnet.edu.au
TO THE EDITOR: In Victoria, notifications
of infectious syphilis infection (primary, sec-
ondary and early latent [< 2 years’ dura-
tion]), reported by the Department of
Human Services, have increased more than
fivefold in the past decade, from 16 in 1995
to 85 in 2004 (Box). An increase in notifica-
tions has also been observed in Sydney.1
Whereas previously in Victoria, very few
infectious syphilis notifications were
reported among men who have sex with
men (1 of 16 cases in 1995), in 2004, 63 of
a total of 85 cases (74%) were in this group
(68% of these were acquired in Victoria).
The Victorian Infectious Diseases Refer-
ence Laboratory (VIDRL) conducts testing
for sexually transmitted infections (STI) and
HIV for three Melbourne sexual health clin-
ics with a high proportion of patients who
are men who have sex with men. In 2004,
62 male patients tested positive for infec-
tious syphilis, and 40% of these were HIV-
positive. This is similar to the situation in
Sydney, where in 2003, 54% of infectious
syphilis cases were reported among HIV-
positive men who have sex with men.1
Syphilis outbreaks among men who have
sex with men have been reported elsewhere
in recent years. There was an outbreak of
syphilis in this group in Greater Manchester;
between 1999 and 2002, and 37% of cases
were in HIV-positive men.2 In this popula-
tion, syphilis infection was associated with
unprotected oral sex with high numbers of
partners, seeking sexual partners at venues
(darkrooms, cruising areas and saunas) and
use of drugs (GHB [gamma hydroxybu-
tyrate] and poppers [amyl nitrate]).3 A San
Fransisco study in 2000, performed in
response to a syphilis outbreak among men
who have sex with men, reported that meet-
ing sexual partners through use of the Inter-
net was a factor significantly associated with
syphilis infection.4
It is likely that some or all of the factors
reported in these outbreaks overseas are
contributing to the sustained increased in
infectious syphilis notifications in Victoria,
but it is important to have local data to
ensure interventions are targeted appropri-
ately and cost effectively. In Victoria,
responses to the increase in syphilis notifica-
tions have already included an alert to gen-
eral practitioners to encourage men who
have sex with men to have syphilis testing
and individual counselling, and syphilis
testing of men who have sex with men at a
popular sex-on-premises venue over a 4-
week period. Depending on further studies
in this population in Victoria, other
responses could include enhancing outreach
at Internet chat rooms, intensive counselling
of HIV-positive men who have sex with
men, and education interventions such as
peer-led community-based strategies for
countering unsafe sex and substance-use
behaviours. Finally, it is vital that interven-
tions are multidisciplinary, collaborative and
evidence-based.
Competing interests: None identified.
1 Jin F, Prestage GP, Kippax SC, et al. Epidemic
syphilis among homosexually active men in Sydney.
Med J Aust 2005; 183: 179-183. 
2 Ashton M, Sopwith W, Clark P, et al. An outbreak no
longer: factors contributing to the return of syphilis
in Greater Manchester. Sex Transm Infect 2003; 79:
291-293.
3 Bellis MA, Cook P, Clark P, et al. Re-emerging
syphilis in gay men: a case-control study of behav-
ioural risk factors and HIV status. J Epidemiol Com-
munity Health 2002; 56: 235-236.
4 Klausner JD, Wolf W, Fischer-Ponce L, et al. Tracing
a syphilis outbreak through cyberspace. JAMA
2000; 284: 447-449. ❏
Locally acquired 
lymphogranuloma venereum 
in a bisexual man
Damon P Eisen
Infectious Diseases Physician, Victorian Infectious 
Diseases Unit, Royal Melbourne Hospital, 
Grattan Street, Parkville, VIC 3050. 
damon.eisen@mh.org.au
TO THE EDITOR: Lymphogranuloma
venereum (LGV) is an uncommon sexually
transmitted infection caused by Chlamydia
trachomatis serovars L1–3. LGV is not
endemic in Australia, and rare Australian
cases of LGV have been seen in patients who
have either acquired the infection while
travelling overseas in an endemic area, or
have had local contact with an imported
case. Currently, there is an outbreak of LGV
in western Europe (in particular, The Neth-
erlands) and the United States.1-4 A case of
LGV in an Australian man with no history of
overseas travel was managed recently.
A 42-year-old bisexual man with pre-
viously treated early syphilis and hepatitis C
infection presented to a Melbourne hospital
in August 2004 complaining of 3 months of
tender right inguinal lymphadenopathy. An
excisional biopsy showed the formation of
necrotising granuloma indicative of LGV. He
had no history of penile ulceration, urethri-
tis or proctitis. The surgical wound healed
normally. The patient gave a history of
attending sex-on-venue premises (“gay sau-
nas”) and “beats”. He reported having oral
sex with men, and recently having non-
insertive sex involving masturbation with an
unknown casual male contact who was
apparently an overseas visitor. The patient
had a female sexual partner with whom he
had irregular, unprotected vaginal inter-
course.
The diagnosis of LGV was confirmed by
polymerase chain reaction (PCR), which
detected C. trachomatis, identified as serovar
L2 by nucleotide sequencing, from the
excised lymph gland. IgG and IgA antibod-
ies to C. trachomatis were demonstrated by
enzyme-immunoassay. Tests for other active
sexually transmitted infections were nega-
tive. The patient was treated with doxycy-
cline (100 mg twice daily for 3 weeks). His
asymptomatic female partner was also
treated.
LGV is endemic in developing countries
in our region, but occurs only sporadically
in industrialised countries. The first stage
of disease consists of a papule or ulcer that
may occur on the penis, urethra or cervix.
Proctocolitis may also be present, mimick-
Infectious syphilis notifications by 
year, Victoria
Data from the Notifiable Infectious Diseases 
Surveillance System Database, Communicable 
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LETTERSing inflammatory bowel disease. Regional
lymphadenopathy develops in the second-
ary stage of disease when there may be
systemic symptoms. Fistula formation at
these sites can be prevented by early recog-
nition and treatment. Late, severe genital
ulceration is rarely seen.
Confirmation of a diagnosis of LGV
requires showing C. trachomatis serovars
L1–3 by serological tests or PCR on geni-
tourinary specimens. Lymph node resec-
tion is not favoured because of the
possibility of sinus formation. Prolonged
treatment with doxycycline or roxithromy-
cin for 3 weeks is required for affected
patients. Asymptomatic contacts are
treated with doxycycline for 1 week or a
single dose of azithromycin.
This case of locally acquired LGV high-
lights the features of this progressive disease
that may now be recognised more frequently
in Australian men who have sex with Euro-
pean or North American men.
Competing interests: Damon Eisen receives sup-
port from the Clinical Centre for Research Excel-
lence in Infectious Diseases, Victorian Infectious
Diseases Service, Royal Melbourne Hospital.
1 Nieuwenhuis RF, Ossewaarde JM, Gotz HM, et al.
Resurgence of lymphogranuloma venereum in
Western Europe: an outbreak of Chlamydia tracho-
matis serovar l2 proctitis in The Netherlands among
men who have sex with men. Clin Infect Dis 2004;
39: 996-1003.
2 Lymphogranuloma venereum among men who
have sex with men — Netherlands, 2003–2004.
MMWR Morb Mortal Wkly Rep 2004; 53: 985-988.
3 ProMED-mail. Lymphogranuloma venereum — USA
(New York City). ProMED-mail 2005; 3 Feb. (Archive
no.: 20050203.0369). Avai lable at: http://
www.promedmail.org (accessed Feb 2005).
4 ProMED-mail. Lymphogranuloma venereum — UK
(England). ProMED-mail 2005; 7 Feb. (Archive no.:
20050207.0416). Available at: http://www.promed-
mail.org (accessed Feb 2005). ❏
Spontaneous bruising, 
haematomata and prolonged 
APTT with meloxicam
Anil M Kurien
General Practitioner, PO Box 717, Gladesville, 
NSW 2111. akurien@bigpond.net.au
TO THE EDITOR: A 47-year-old woman
presented with a 1-week history of spontan-
eous prominent and painful bruising and
haematomata, 5–6 weeks after commencing
meloxicam 15 mg daily for osteoarthritis
and plantar fasciitis. The bruises varied in
size from 2 cm   2 cm to 3 cm   4 cm. She
had a past history of acne rosacea, for which
she was taking clonidine 100 μg daily, and
reflux oesophagitis, for which she was tak-
ing pantoprazole 40 mg daily.
Meloxicam, being the only new drug
taken by the patient, was suspected as the
causative agent and was therefore discontin-
ued. Activated partial thromboplastin time
(APTT) at presentation was 58 s (reference
range, 22s–38 s). A week after stopping
meloxicam, it had fallen to 37 s. All other
haematological parameters, including plate-
let count and international normalised ratio,
were normal, as were renal and liver func-
tion. New bruises and haematomata stopped
appearing 2 days after the patient stopped
taking meloxicam. She continued taking
clonidine and pantoprazole.
Meloxicam is a selective nonsteroidal anti-
inflammatory drug (NSAID) (a cyclo-oxyge-
nase 2 [COX-2] inhibitor). It was chosen for
this patient in view of her reflux oesophagi-
tis and because she had already been unre-
sponsive clinically to one of the other COX-
2 inhibitors. Unlike non-selective NSAIDs,
meloxicam has been shown to have negligi-
ble effect on platelet function as measured
by bleeding time.1-3 Rinder et al4 reported
no prolongation of APTT or prothrombin
time after 8 days of regular administration of
meloxicam at 7.5 mg, 15 mg or 30 mg.
In spite of these contrary findings, I
believe the prolongation of APTT and spon-
taneous bruising and haematomata in this
patient were directly attributable to meloxi-
cam, as the bruises disappeared 2–3 days
after stopping the drug (with no other
changes in the patient’s existing medication)
and a repeat APTT a week after cessation of
the drug was normal.
1 Knijff-Dutmer EAJ, Kalsbeek-Batenburg EM, Koerts
J, van de Laar MA. Platelet function is inhibited by
non-selective non-steroidal anti-inflammatory drugs
but not by cyclo-oxygenase-2-selective inhibitors in
patients with rheumatoid arthritis. Rheumatology
(Oxford) 2002; 41: 458-461.
2 Van Hecken, Schwartz JI, Depre M, et al. Compara-
tive inhibitory activity of rofecoxib, meloxicam,
diclofenac, ibuprofen and naproxen on COX-2 ver-
sus COX-1 in healthy volunteers. J Clin Pharmacol
2000; 40: 1109-1120.
3 Stichtenoth DO, Wagner B, Frolich JC. Effects of
meloxicam and indomethacin on cyclooxygenase
pathways in healthy volunteers. J Investig Med
1997; 45: 44-49.
4 Rinder HM, Tracey JB, Souhrada M, et al. Effects of
meloxicam on platelet function in healthy adults: a
randomized, double-blind, placebo-controlled trial.
J Clin Pharmacol 2002; 42: 881-886. ❏
A potential link between 
magnesium intake and 
diabetes in Indigenous 
Australians
Diane A Longstreet,* Deanne L Heath,† 
Robert Vink‡
* Dietitian, † Research Scientist, Townsville Aboriginal 
and Islander Health Services, 57–59 Gorden Street, 
Garbutt, QLD 4814; ‡ Head, Department of Pathology, 
University of Adelaide, SA. 
dlongstreet@taihs.net.au
TO THE EDITOR: Diabetes in Indigenous
Australians occurs at a younger age and at
almost four times the rate in non-Indigen-
ous Australians. The age-adjusted preva-
lence of diabetes among Indigenous people
is 16% in remote areas and 9% in non-
remote areas, with the actual prevalence
estimated to be between 20% and 25%, and
possibly higher than 30% in some remote
areas.1 The cause for this disparity in diabe-
tes incidence is multifactorial, and recent
evidence suggests that nutrition — particu-
larly magnesium intake — may play a role.
Although central obesity remains a major
risk factor, magnesium deficit has been pos-
ited to be an underlying common mecha-
nism for the insulin resistance found in type
2 diabetes, as well as in metabolic syn-
drome, hypertension, and impaired glucose
tolerance.2 The clinical correlations between
low magnesium and diabetes have been well
documented,3 with serum magnesium defi-
cits being reported in 25%–39% of diabetic
Histological section of the lymph 
node showing the thickened node 
capsule and necrotising granuloma
Image courtesy of Dr Malcolm Buchanan, 
Department of Anatomical Pathology, Royal 
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LETTERSoutpatients in the United States and Switzer-
land, and up to 73% of diabetic outpatients
in Mexico.
With magnesium deficits being observed
in diabetes, studies examining the effects of
magnesium-rich foods on diabetes risk
become relevant. The Nurses’ Health Study
and the Health Professionals’ Follow-up
Study, which included 85 060 women (18
years follow-up) and 42 872 men (12 years
follow-up), demonstrated that, after adjust-
ing for confounding variables, a magnes-
ium-rich diet reduced the relative risk of
developing diabetes by 34% in women and
33% in men.4 A similar inverse correlation
between magnesium intake and diabetes
risk was shown in the Iowa Women’s Health
Study with a cohort of 35 988 older
women,5 and in the Honolulu Heart Pro-
gram and the Women’s Health Study with
cohorts of 8006 men and 39 345 women,
respectively.6,7
Despite this growing body of evidence
supporting the involvement of magnesium
in diabetes, consideration of magnesium
status has not been integrated into Austral-
ian medical care for diabetes, and more
specifically, for Indigenous Australians. It is
known that the traditional diet of hunter-
gathers such as Indigenous Australians was
much more nutrient- and magnesium-rich
than the current estimated Australian
intake.8 Nonetheless, there remains a lack of
information about current magnesium sta-
tus, including dietary intake, in Indigenous
Australians.
It is possible that dietary magnesium
intake may be too low to maintain normal
serum magnesium homoeostasis, and that
this might contribute to the development of
type 2 diabetes. Further research into this
issue may provide this information.
1 Thomson N, Burns J, Burrow S, Kirov E. Diabetes.




2 Barbagallo M, Dominguez LJ, Galioto A, et al. Role
of magnesium in insulin action, diabetes and car-
dio-metabolic syndrome X. Mol Aspects Med 2003;
24: 39-52.
3 Walti MK, Zimmermann MB, Spinas GA, Hurrell RF.
Low plasma magnesium in type 2 diabetes. Swiss
Med Wkly 2003; 133: 289-292.
4 Lopez-Ridaura R, Willett WC, Rimm EB, et al. Mag-
nesium intake and risk of type 2 diabetes in men
and women. Diabetes Care 2004; 27: 134-140.
5 Meyer KA, Kushi LH, Jacobs DR Jr, et al. Carbohy-
drates, dietary fiber, and incident type 2 diabetes in
older women. Am J Clin Nutr 2000; 71: 921-930.
6 Abbott RD, Ando F, Masaki KH, et al. Dietary
magnesium intake and the future risk of coronary
heart disease (the Honolulu Heart Program). Am J
Cardiol 2003; 92: 665-669.
7 Song Y, Manson JE, Buring JE, Liu S. Dietary mag-
nesium intake in relation to plasma insulin levels
and risk of type 2 diabetes in women. Diabetes
Care 2004; 27: 59-65.
8 Eaton SB, Eaton SB 3rd. Paleolithic vs. modern diets
— selected pathophysiological implications. Eur J
Nutr 2000; 39: 67-70. ❏
Venous thromboembolism: 
diagnosis and management 
of pulmonary embolism
Matthew J Bragg
Emergency Physician, Prince of Wales Hospital, 
Barker Street, Randwick, NSW 2031. 
braggm@sesahs.nsw.gov.au
TO THE EDITOR: The clinical update on
venous thromboembolism by Lee and col-
leagues advises that “Ventilation perfusion
(V/Q) isotope scanning reliably establishes
the diagnosis of PE [pulmonary embolism] if
the V/Q features suggest a high probability
of PE.. .”.1 Although this is probably true for
patients with intermediate or high pretest
probability, a discordant result (low pretest
probability and high probability V/Q)
should be regarded with suspicion.
From the original PIOPED data, high
probability V/Q was predictive of angio-
graphically confirmed PE in 80% of
patients,2 which drops to 56% by Bayesian
analysis if the pretest probability is low.
False positive results may be due to previous
PE or unrelated parenchymal lung disease.
There is significant potential morbidity asso-
ciated with a false positive result for PE,
both from the acute anticoagulation and for
future presentations with PE-type symp-
toms, where PE will be accorded a higher
probability because of the previous docu-
mented diagnosis.
As Lee and colleagues also state, D-dimer
testing must be combined with an estimate
of pretest probability to be useful. They
advocate excluding PE on the basis of low
pretest probability and negative D-dimer
result. However, a negative D-dimer result
(rapid enzyme-linked immunosorbent assay
[ELISA] type) may be used to exclude PE in
intermediate as well as low probability
patients.3 This is dependent on the type of
assay available as well as the local PE preva-
lence, and local guidelines should therefore
be developed.
1 Lee CH, Hankey GJ, Ho WK, Eikelboom JW. Venous
thromboembolism: diagnosis and management of
pulmonary embolism. Med J Aust 2005; 182: 569-
574. 
2 PIOPED Investigators. Value of the ventilation/per-
fusion scan in acute pulmonary embolism: results of
the prospective investigation of pulmonary embo-
lism diagnosis (PIOPED). JAMA 1990; 263: 2753-
2759.
3 British Thoracic Society Standards of Care Commit-
tee Pulmonary Embolism Guideline Development
Group. British Thoracic Society guidelines for the
management of suspected acute pulmonary embo-
lism. Thorax 2003; 58: 470-484. ❏
Paul M Bailey
Emergency Physician, Joondalup Health Campus, 
Shenton Avenue, Joondalup, WA 6027. 
paul.bailey@gmail.com
TO THE EDITOR: I read with interest the
article by Lee et al regarding the investiga-
tion and treatment of pulmonary embolism
(PE).1 The investigation of patients present-
ing with PE as a diagnostic possibility is of
great interest to emergency physicians, and
such presentations are a daily occurrence in
emergency departments around the country.
Unfortunately, only a small amount of text
is devoted to describing the relative merits of
ventilation perfusion (V/Q) scanning and
computed tomography pulmonary angiog-
raphy (CTPA), and no guidance is provided
as to which is the test of choice when both
are available. The British Thoracic Society
has recommended CTPA as the lung imag-
ing modality of first choice for patients
presenting with non-massive PE.2 There is a
large and increasing body of evidence that
CTPA provides superior specificity to V/Q
scanning in the detection of PE. CTPA also
provides the opportunity of establishing
diagnoses other than PE and, in addition, a
negative multi-slice CTPA is of sufficient
sensitivity to enable the withholding of anti-
coagulation.3 It is also my experience that
CTPA is easier to obtain out of hours, com-
pared with V/Q scanning.
The authors state that V/Q scanning
“reliably establishes the diagnosis of PE if
the V/Q scan features suggest a high proba-
bility of PE. ..”.1 Unfortunately, this state-
ment is incorrect. It is essential that V/Q
scan results be interpreted in the light of the
patient’s clinical probability for PE. In the
PIOPED study, only 56% of patients with
high probability V/Q scan reports had pul-
monary embolism if the pretest probability
was low.4
No mention is made of the special situa-
tion of pregnant women presenting with
pleuritic pain, or which lung imaging test is
considered “safest” for both mother and
baby. Although the risks of PE are generally
agreed to be increased in pregnancy, it is my
experience that pregnant women are
extremely reluctant to undergo any form of
diagnostic investigation that exposes the
fetus to radiation.220 MJA • Volume 183 Number 4 • 15 August 2005
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the assessment of PE in emergency depart-
ment patients only, and provide a means for
clinicians with little experience to make an
accurate assessment of an individual
patient’s clinical probability of PE.5 Once
initiated, clinical assessment of the patient
with possible PE is straightforward. The key
question facing emergency physicians is
this: is there a group of patients that have
such low probability for PE that no investi-
gation at all is required?
1 Lee C, Hankey G, Ho W, Eikelboom J. Venous
thromboembolism: diagnosis and management of
pulmonary embolism. Med J Aust 2005; 182: 569-
574. 
2 British Thoracic Society Standards of Care Commit-
tee Pulmonary Embolism Guideline Development
Group. British Thoracic Society guidelines for the
management of suspected acute pulmonary embo-
lism. Thorax 2003; 58: 470-484.
3 Perrier A, Roy PM, Sanchez O, et al. Multidetector-
row computed tomography in suspected pulmon-
ary embolism. N Engl J Med 2005; 352: 1760-1768.
4 PIOPED Investigators. Value of the ventilation/per-
fusion scan in acute pulmonary embolism: results of
the prospective investigation of pulmonary embo-
lism diagnosis (PIOPED). JAMA 1990; 263: 2753-
2759.
5 Wells PS, Anderson DR, Rodger M, et al. Excluding
pulmonary embolism at the bedside without diag-
nostic imaging: management of patients with sus-
pected pulmonary embolism presenting to the
emergency department by using a simple clinical
model and D-dimer. Ann Intern Med 2001; 135: 98-
107. ❏
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237 Barton Street East, Hamilton, ON L8L2X2, Canada; 
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IN REPLY: Pulmonary embolism (PE)
remains a complex diagnosis despite the
availability of validated prediction models
and D-dimer testing to direct the need for
diagnostic imaging.
We agree with Bailey that the ability to
exclude the diagnosis of PE on clinical
grounds in patients with a low pretest proba-
bility is highly desirable. Unfortunately, clin-
ical features lack sensitivity and specificity
for the diagnosis of PE, and clinical predic-
tion models, laboratory investigations, and
diagnostic imaging are likely to remain an
integral part of the clinical work-up.
As suggested by Bragg, it may be possible
to simplify the diagnostic approach by using
a highly sensitive D-dimer assay, and simpli-
fied pretest probability models have been
proposed. However, this may come at a cost
of reduced specificity,1 which leads to unnec-
essary diagnostic imaging studies and thus
limits the clinical utility of these approaches.
Further improvements in the diagnostic
approach to PE are clearly needed.
There are emerging data demonstrating
the accuracy of computed tomography pul-
monary angiography (CTPA) for the diagno-
sis of PE. However, CTPA has limitations (a
large contrast load, high radiation dose, and
lack of sensitivity of first generation scan-
ners for small thrombi2), some of which are
evident in the recently published validation
study referred to by Bailey:3 25% of
screened patients with suspected PE were
not eligible for this study because of renal
impairment, a contraindication to CT, or
other reasons.
The diagnostic algorithm that we pro-
vided in our review suggests that either
ventilation perfusion (V/Q) scanning or
CTPA can be used for patients with sus-
pected PE who require diagnostic imaging,2
with the choice determined by patient fac-
tors and availability.
The diagnosis of PE during pregnancy is
challenging because of concerns about radi-
ation exposure and uncertainty about
whether CTPA or V/Q delivers more radia-
tion to the fetus.4 Furthermore, clinical
decision rules have not been validated in
pregnancy. However, recommendations
from experts and professional bodies sug-
gest that V/Q scanning can be used in
combination with compression ultrasound
to establish or exclude the diagnosis of PE
during pregnancy in most cases with mini-
mal fetal radiation exposure.5,6
The comments by Bailey and Bragg con-
cerning the interpretation of high probability
V/Q scan results highlight the pitfalls of
performing diagnostic imaging without con-
sidering the patient’s pretest probability of
PE. Although a high probability V/Q scan is
diagnostic in patients with a moderate or
high pretest probability of PE (prevalence of
disease  90%), the prevalence of disease is
only about 50% in those with a low pretest
probability.7,8 Therefore, V/Q scanning
should not be performed in patients with a
low pretest probability unless the D-dimer
test is positive. In this situation the algorithm
for moderate or high pretest probability
should be followed,2 and a high probability
scan reliably establishes the diagnosis.
1 Carrier M, Wells PS, Rodgers MA. Excluding
pulmonary embolism at the bedside with a low
pretest probability and D-dimer: safety and the
clinical utility of full methods to assign pretest
probability. Thromb Res 2005. In press.
2 Lee C, Hankey GJ, Ho W, Eikelboom JW. Venous
thromboembolism: diagnosis and management of
pulmonary embolism. Med J Aust 2005; 182: 569-
574. 
3 Perrier A, Roy PM, Sanchez O, et al. Multi-detector-
row computed tomography in suspected pulmon-
ary embolism. N Engl J Med 2005; 352: 1760-1768.
4 Winer-Muram HT, Boone JM, Brown HL, et al.
Pulmonary embolism in pregnant patients: fetal
radiation dose with helical CT. Radiology 2002; 224:
487-492.
5 Bates SM, Ginsberg JS. How we manage venous
thromboembolism during pregnancy. Blood 2002;
100: 3470-3478.
6 ACOG Committee on Obstetric Practice. ACOG
Committee Opinion. Number 299, September 2004
(replaces No. 158, September 1995). Guidelines for
diagnostic imaging during pregnancy. Obstet
Gynecol 2004; 104: 647-651.
7 PIOPED Investigators. Value of the ventilation/per-
fusion scan in acute pulmonary embolism: results of
the prospective investigation of pulmonary embol-
ism diagnosis (PIOPED). JAMA 1990; 263: 2753-
2759.
8 Hull RD, Hirsh J, Carter CJ, et al. Diagnostic value of
ventilation-perfusion lung scanning in patients with
suspected pulmonary embolism. Chest 1985; 88:
819-828. ❏
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thrombosis by 
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Richard F O’Reilly,* Ian A Burgess,† 
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TO THE EDITOR: In a recent editorial,
Gallus estimates the cost of doing ultra-
sonography in all patients after unilateral
hip or knee replacement, with further test-
ing in the 9% or 26% of patients, respec-
tively, found to have deep vein thrombosis
(DVT), to be about $200 000 per 1000
patients.1 We agree.
He then states, “Many would argue that
extended prophylaxis is likely to be the sim-
plest, cheapest and perhaps safest solution”.
However, prophylaxis is also expensive.
Subcutaneous enoxaparin 40 mg adminis-
tered daily for 30 days costs $170, or
$170 000 per 1000 patients.2
In our study, we found DVTs in 1086 of
5999 patients (18.1%) before discharge,3 so
that extended prophylaxis would involve
81.9% of patients receiving prophylactic
doses of anticoagulants, with the risk of
unwanted bleeding, despite the absence of
DVT on ultrasound at Day 7 postoperatively.
In addition, if an ultrasound scan was not
done before discharge, the 18.1% of patientsMJA • Volume 183 Number 4 • 15 August 2005 221
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(not therapeutic) doses of anticoagulant for
their DVT.
We plan a further study to check the preva-
lence of post-discharge DVT by repeating
ultrasonography at 90 days postoperatively in
patients without DVT on ultrasound at Day 7.
We suspect the prevalence is lower than sug-
gested in the literature, as the data on late
presentation of DVTs have been obtained by
retrospective study of the number of patients
re-admitted to hospital with DVT.
Finally, on the question of whether per-
forming ultrasonography on all patients has
clinical benefit, we concur with Gallus when
he writes that “Logic suggests it should. ..”.
Competing interests: Richard O’Reilly has received
speaker fees and travel assistance to attend meet-
ings from AstraZeneca.
1 Gallus A. Screening for venous thrombosis by ultra-
sonography before hospital discharge after major
joint surgery [editorial]. Med J Aust 2005; 182: 149-150.
2 Australian Government Department of Health and
Ageing. Schedule of pharmaceutical benefits for
approved pharmacists and medical practitioners.
1 April 2005. Available at: http://www1.health.gov.au/
pbs (accessed Jul 2005).
3 O’Reilly RF, Burgess IA, Zicat B. The prevalence of
venous thromboembolism after hip and knee replace-
ment surgery. Med J Aust 2005; 182; 154-159. ❏
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IN REPLY: O’Reilly and colleagues belatedly
address the need to consider bleeding risk
and costs when choosing between manage-
ment routines designed to prevent venous
thrombosis and pulmonary embolism. Their
otherwise valuable article1 failed to record
bleeding rates when patients (almost 17%)
with subclinical calf-vein thrombosis were
exposed to therapeutic (not prophylactic)
anticoagulant dosages. Nor did they evalu-
ate the dollar and manpower costs of their
complex management routines.
Present evidence-based international
guidelines from the Seventh ACCP (Ameri-
can College of Chest Physicians) Conference
on Antithrombotic and Thrombolytic Ther-
apy recommend effective prophylaxis for at
least 10 days in all patients having hip or
knee replacement, extending to 28–35 days
after hip replacement.2 The ACCP guide-
lines also recommend against routine use of
ultrasound screening because it is “neither
clinically effective nor cost effective”.2 This
is a Grade 1A recommendation from the
ACCP (“Grade 1” implies certainty “that the
benefits do, or do not, outweigh the risks,
burdens, and costs”; “Grade A” refers to
recommendations based on “randomized
clinical trials with consistent results [that]
provide evidence with a low likelihood of
bias”).3 To reverse this recommendation
would require randomised comparisons
between routine prophylaxis alone or rou-
tine prophylaxis supplemented by screening
ultrasonography — powered to permit
meaningful measures, in both groups, of
thromboembolism rates, bleeding rates and
costs. Routinely screening for subclinical
thrombosis after major joint surgery should
not be done outside suitably designed clini-
cal trials until such evidence is available.
The role of logic in medicine is to generate
hypotheses, which must then be tested by
clinical trial. Unfortunately, evidence
derived from uncontrolled cohort studies
remains limited to Grade C (based on
“observational studies or [on] generalization
from one group of patients included in
randomized trials to a different, but some-
what similar, group of patients”).3
Competing interests: The author has received con-
sulting fees for participating in clinical trial steering
committees (from Sanofi, Bristol-Myers Squibb,
Bayer and Organon) and expert committees (from
AstraZeneca, Bayer and CSL).
1 O’Reilly RF, Burgess IA, Zicat B. The prevalence of
venous thromboembolism after hip and knee
replacement surgery. Med J Aust 2005; 182: 154-159. 
2 Geerts WH, Pineo GF, Heit JA, et al. Prevention of
venous thromboembolism: the Seventh ACCP Con-
ference on Antithrombotic and Thrombolytic Ther-
apy. Chest 2004; 126 (3 Suppl): 338S-400S.
3 Guyatt G, Schunemann HJ, Cook D, et al. Applying
the grades of recommendation for antithrombotic
and thrombolytic therapy: the Seventh ACCP Con-
ference on Antithrombotic and Thrombolytic Ther-
apy. Chest 2004; 126 (3 Suppl): 179S-187S. ❏
Familial 
hypercholesterolaemia: 
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Ian Hamilton-Craig
Chairman, MEDPED-FH Australia, North Adelaide 
Heart Centre, 80 Brougham Place, North Adelaide 
SA 5006. Ihc@sahc.com.au
TO THE EDITOR: In their editorial, Bur-
nett and colleagues correctly emphasise the
importance and cost-effectiveness of cascade
family screening in the early diagnosis of
familial hypercholesterolaemia (FH) among
relatives of known cases. They point out that
Australia does not have “a national program
for detecting the vast majority of patients
with FH in our community.. .”.1
Such an approach has been advocated
since the 1980s by the international
MEDPED-FH project, initiated in Utah to
raise public and professional awareness of
the need to detect and treat FH at an early
age (MEDPED-FH stands for Make Early
Diagnosis to Prevent Early Deaths in Famil-
ial Hypercholesterolaemia).2 Since then, the
project has spread to over 30 countries,
including Australia, and has over 25 000
patients with FH registered worldwide.3
In Australia, the MEDPED-FH program
has registered about 700 patients with FH,
about 2% of the estimated 33 000 patients
overall.4 This proportion is similar to regis-
trations in many other countries (including
the US). Only the Netherlands, Denmark
and Finland, where government-financed
screening programs are in place, have higher
proportions of registrations, with 10%–50%
of patients with FH registered with
MEDPED-FH. Also, in these countries, DNA
detection of low-density lipoprotein choles-
terol receptor gene mutations is used rou-
tinely for the diagnosis of FH.
At present in Australia, nurse practition-
ers are performing FH cascade screening in
collaboration with MEDPED-FH physicians
in each capital city, supported by Pfizer
Australia. Further work on FH is being
carried out by Associate Professor David
Sullivan and colleagues in Sydney, sup-
ported by the Western and Central Sydney
Area Health Services.
In addition, the Cardiac Society of Australia
and New Zealand has established a working
party to investigate cardiac genetic disorders,
including FH, and is involved in further edu-
cation among cardiologists regarding screen-
ing, diagnosis and treatment of FH.
But these efforts are not enough. I support
Burnett and colleagues in recommending
the establishment of a nationwide screening
program for FH, and also recommend that
DNA diagnosis be incorporated as an essen-
tial component. There is a definite cost
benefit of early detection and treatment with
statins of patients with FH.
1 Burnett J, Ravine D, van Bockxmeer FM, Watts GF.
Familial hypercholesterolaemia: a look back, a look
ahead [editorial]. Med J Aust 2005; 182: 552-553. 
2 Hamilton-Craig I, for the Australian MED-PED FH
Steering Committee. Make early diagnosis, prevent
early death from familial hypercholesterolaemia. The
MED-PED FH program. Med J Aust 1995; 162: 454-455.
3 Williams RR, Hamilton-Craig I, Kostner GM, et al. MED-
PED: an integrated national strategy for preventing
early deaths. In: Berg K, Boulyjenkov V, Christen Y,
editors. Genetic approaches to noncommunicable dis-
eases. Berlin: Springer-Verlag, 1996: 35-45.
4 Hamilton-Craig I. Case-finding for familial hyper-
cholesterolemia in the Asia-Pacific region. Semin
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IN REPLY: The international MEDPED-FH
project has made a major contribution
towards introducing family-based cascade
screening into the Australian health care
system. Although these achievements are
important, we agree with Hamilton-Craig’s
view that they are dwarfed by the magnitude
of what now has to be done to deliver to all
at-risk relatives the health gains that can be
achieved by a proactive program of popula-
tion screening.
The risk of familial hypercholesterolaemia
(FH) for a first-degree relative of an affected
index case is 250 times greater than the risk
for a member of the general population. The
relative cost-efficiency of family-based cas-
cade genetic screening is high, compared
with population-wide screening for a domi-
nantly inherited disorder.1,2
We disagree with Hamilton-Craig that
DNA diagnosis is an essential component of
an effective screening program. Among FH-
affected families, biochemical testing has a
sensitivity of 95%, and a specificity of 96%.3
The additional diagnostic gain from DNA
testing in the context of screening relatives
at 50% prior risk is marginal, although of
use in determining with certainty whether
or not a relative has inherited the family-
specific trait.
FH offers a paradigm of best clinical
practice for improving health care outcomes
for a widening range of “monogenic” disor-
ders with complications that can be avoided
or reduced by focused health care provision.
The time has come when physicians, cardi-
ologists, paediatricians, biochemists, geneti-
cists, public health physicians, general
practitioners and those administering the
funding of health care delivery in Australia
come together and formulate the changes
necessary to allow cascade genetic screening
for FH to become part of routine health care.
1 Krawczak M, Cooper DN, Schmidtke J. Estimating
the efficacy and efficiency of cascade genetic
screening. Am J Hum Genet 2001; 69: 361-370.
2 Leren TP. Cascade genetic screening for familial
hypercholesterolemia. Clin Genet 2004; 66: 483-
487.
3 Thorsson B, Sigurdsson G, Gudnason V. Systematic
family screening for familial hypercholesterolemia in
Iceland. Arterioscler Thromb Vasc Biol 2003; 23:
335-338. ❏
A picture of Australia’s children
Caroline F Finch
Director, New South Wales Injury Risk Management 
Research Centre, University of New South Wales, 
Level 8, Applied Science Building, Sydney, NSW 2052. 
c.finch@unsw.edu.au
TO THE EDITOR: I am prompted to write
to you in response to a recent MJA editorial.1
It amazes me that the health sector in Aus-
tralia, as I think the editorial did, continues to
largely ignore the magnitude of the problem
of injury in our children. This is despite clear
evidence of the excess ill-health burden that
injury places on our children, according to
the Australian Institute of Health and Welfare
(AIHW) report (the subject of the editorial)2
and other reports.3-5
Having said this, the editorial did high-
light a very pleasing trend — there has been
a steady decline in injury deaths in later
childhood. Unfortunately, however, this was
the only mention of injury in the editorial,
and readers could be forgiven for thinking
that this is the end of the story: the injury
death rate is declining; therefore, we are
doing all we can, and injuries are not a
major issue. Nothing could be further from
the truth. Our children continue to die from
road and drowning accidents and will do so
until injury prevention is recognised as par-
amount.
The AIHW report clearly states that the
single highest cause of death in children
remains injury and poisoning.2 Accordingly,
trauma is the single highest contributor to
premature mortality and years of potential
life lost of any health condition in Australia.
If we don’t develop new approaches to
reducing the incidence of drownings and
road deaths, in particular, we will not see
further declines in injury-related death
rates, and injury will continue to rate highly
as a killer of young people.
Importantly, injuries do not only kill
young people — they also hospitalise and
maim them. The second most common rea-
son for hospitalisation in Australian children
is injury.2 Unlike injury deaths, there has
been no trend in the rate of hospitalisation
for injury. Across age groups, there appears
to be a shift from fatalities to an increasing
number of people with a high lifetime bur-
den of significant disability, including brain
and spinal cord damage. Imagine what this
does to the quality of life and life expectancy
of a child. How many of these children will
be able to lead physically active lives?
It is time for the health sector, particularly
public health agencies, to properly recognise
injury as a critical issue for the ongoing
health of Australian children and to formally
commit to appropriate preventive actions,
commensurate with the priority ranking of
childhood injuries.
1 Patton GC, Goldfeld SR, Pieris-Caldwell I, et al. A
picture of Australia’s children [editorial]. Med J Aust
2005; 182: 437-438. 
2 Australian Institute of Health and Welfare. A picture
of Australia’s children. Canberra: AIHW, 2005. Avail-
able at: http://www.aihw.gov.au/publications/
index.cfm/title/10127/ (accessed Jul 2005).
3 Schmertmann M, Finch C, Williamson A. NSW injury
profile: a review of injury deaths during 1998-2002.
Sydney: NSW Injury Risk Management Research
Ce n tre ,  2 0 0 4.  Ava i l a b l e  a t :  h t tp : / /
www.irmrc.unsw.edu.au/Publications/centrere-
ports.asp (accessed Jul 2005).
4 NSW Child Death Review Team. Annual report
January–December 2003. Sydney: NSW Commis-
sion for Children and Young People, 2004. Available
at: http://www.kids.nsw.gov.au/publications/
cdrt2003.html (accessed Jul 2005).
5 Strategic Injury Prevention Partnership (SIPP). The
draft national injury prevention plan: 2004 onwards.
Canberra: SIPP, 2004. Available at: http://
www.nphp.gov.au/workprog/sipp/documents/
draftnipp_190804_000.pdf (accessed Jul 2005). ❏
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IN REPLY: There is little to disagree with in
this excellent summary of injury morbidity
and mortality in Australian children. How-
ever, the principal point of our editorial1
was to highlight important problems where
adequate data are currently unavailable.
The Australian Institute of Health and Wel-
fare report was able to give extensive cover-
age to injuries and accidents in children.2
Indeed, seven indicators specifically
addressed aspects of childhood injury, with a
range of others (eg, child abuse and neglect,
neighbourhood safety) addressing relevant
aspects of the family and social context. This
emphasis reflected not only the importance
of childhood injury, but the extent to which
reasonably good data are available.
We agree that, despite some favourable
mortality trends, the burden of childhood
injury remains high, as are associated health
care costs. However, childhood injury is an
area where advocacy has translated into
action.3 One of the reasons for the success of
that advocacy has been the availability ofMJA • Volume 183 Number 4 • 15 August 2005 223
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sound data, both to make the case and to
ensure an appropriate focus in policy
responses.4 While there is undeniably much
more to do, we can learn much from injury
prevention about how to tackle the newly
emerging problems of childhood.
1 Patton GC, Goldfeld SR, Pieris-Caldwell I, et al. A
picture of Australia’s children [editorial]. Med J Aust
2005; 182: 437-438. 
2 Australian Institute of Health and Welfare. A picture
of Australia’s children. Canberra: AIHW; 2005. Avail-
able at: http://www.aihw.gov.au/publications/
index.cfm/title/10127/ (accessed Jul 2005).
3 Strategic Injury Prevention Partnership (SIPP). The
draft national injury prevention plan: 2004 onwards.
Canberra: SIPP, 2004. Available at: http://
www.nphp.gov.au/workprog/sipp/documents/
draftnipp_190804_000.pdf (accessed Jul 2005).
4 Pointer S, Harrison J, Bradley C. National injury
prevention plan priorities for 2004 and beyond:
discussion paper. Injury Research and Statistics
Series Number 18. Adelaide: Australian Institute for
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TO THE EDITOR: Reilly et al draw atten-
tion to the lack of research on the impact of
the findings of physical examination on
patient care, and state that, in the United
States, many doctors “do not know how to
do it, and do not see why they should”.1
Should we continue to teach these skills in
Australia?
Experience tells us, even if research does
not, that the presence or absence of one or
more physical findings may make a crucial
difference to patient care. The important
thing for teachers is that, while students learn
the rituals, we should encourage them to
think critically about what they are doing.
They focus on passing the next objective
structured clinical examination (OSCE),
which often requires them to carry out a
ritual. They are vaguely aware they will be
required to think selectively about real
patients and the necessity to make a diagno-
sis, but have little practice in selecting appro-
priate physical examination. We who teach
them should formally recognise the distinc-
tion between ability to perform and ability to
choose and interpret physical signs.
I learned an inductive process: take a
history and perform a complete examina-
tion, and then engage the brain. Research
would not tolerate such a “fishing trip”! The
inductive method has been replaced by a
hypothetico-deductive approach. This is
criticised, but all doctors take intelligently
selected short cuts. We should acknowledge
this and critically examine the skill.
Students must learn systematic examina-
tion. This is the repertoire from which they
choose when faced with a clinical problem.
OSCEs early in the undergraduate course
should assess their competence in this, and
students should know exactly what they are
to do. Our bedside clinical teaching and
later OSCEs should explicitly challenge stu-
dents to consider the selection of relevant
clinical examination required in the light of
the history, just as they should consider the
value of all other tests, rather than using a
blunderbuss approach.
Together, history and physical examina-
tion have two objectives. One is diagnosis;
the other defines or excludes comorbidity.
Without them, medical care cannot begin to
function effectively or economically.
Neither I nor your authors are bewitched;
their anecdotes make this clear, and they
define the reasons for the lack of research. A
focus on considering what can, and cannot,
be gained by selective physical examination
should reduce our own and our students’
bother and bewilderment.
1 Reilly BM, Smith CA, Lucas BP. Physical examina-
tion: bewitched, bothered and bewildered [edit-
orial]. Med J Aust 2005; 182: 375-376. ❏
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